title: Pasteurized tumoral autograft and adjuvant chemotherapy for the treatment of canine distal radial osteosarcoma: 13 cases.
abstract: OBJECTIVE
  To report outcome in 13 dogs with distal radial osteosarcoma, without evidence of metastasis, treated by a combination of adjuvant chemotherapy and a pasteurized autograft limb-sparing procedure.
  
  
  METHODS
  Prospective clinical study.
  
  
  METHODS
  Thirteen dogs with distal radial osteosarcoma.
  
  
  METHODS
  Limb-sparing procedure was performed using an autograft from the excised tumoral segment, pasteurized at 65 degrees C for 40 minutes. Adjuvant chemotherapy (cisplatin or cisplatin and doxorubicin) was administered in all dogs.
  
  
  RESULTS
  Mean and median survival times were 531 and 324 days, respectively (range, 180 to 1,868 days). Overall survival was 100% at 6 months, 50% at 12 months, 44% at 18 months, and 22% at 24 months. Lung metastasis occurred in 5 (38%) dogs. Observed complications were local recurrence (2 dogs, 15%), allograft infection (4 dogs, 31%), and implant failure (3 dogs, 23%). Limb function was good in 12 dogs (92%) and fair in 1 dog.
  
  
  CONCLUSIONS
  Pasteurized bone autograft derived from the tumoral bone segment was an effective alternative to cortical bone allograft for limb sparing in canine distal radial osteosarcoma, in terms of feasibility, pattern of healing, complications, and survival.
  
  
  CONCLUSIONS
  Use of a pasteurized bone autograft eliminates the need for a canine bone allograft bank and has the added advantage of good fit to the recipient site.
authors.affiliation: Dipartimento di Patologia Animale, School of Veterinary Medicine, Turin, Italy.
authors.forename: Emanuela
authors.initials: E
authors.lastname: Morello
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Vasconi
authors.forename: Marina
authors.initials: M
authors.lastname: Martano
authors.forename: Bruno
authors.initials: B
authors.lastname: Peirone
authors.forename: Paolo
authors.initials: P
authors.lastname: Buracco
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000662:veterinary*; D016025:Bone Transplantation / Q000379:methods / Q000662:veterinary*; D017024:Chemotherapy, Adjuvant / Q000662:veterinary; D002945:Cisplatin / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D004285:Dogs; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D008175:Lung Neoplasms / Q000556:secondary / Q000662:veterinary; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000662:veterinary; D012516:Osteosarcoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000662:veterinary*; D011183:Postoperative Complications / Q000662:veterinary; D011446:Prospective Studies; D011884:Radius / Q000473:pathology; D016019:Survival Analysis; D014182:Transplantation, Autologous / Q000662:veterinary; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; D002945:Cisplatin